Oral ASH

There were a few autoimmune toxicities seen in this trial. They weren't dramatic and they didn't seem to be associated with responses. I don't think oral ASH is going to be worth the trouble in MDS. We already have an oral drug that can be combined with Venetlax. That is a high risk MDS. The oral ASH may have a role in the maintenance therapy, maybe after ASH-VEN, in older adults or maybe in the maintenance after transplant. There's a lot of ways to use it. But I don't see the path forward to anything beyond the Quasar trial right now.